Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dwinell, Michael B.
Funding for this research was provided by:
National Cancer Institute (U01 CA178960)
Polish National Science Centre (No. 2015/18/E/ST4/00235)
Version of Record valid from 2017-04-21